Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension

Cardiovascular Drugs and Therapy

Volumn 11, Issue 5, 1997, Pages 619-627

  Pittrow, David Bernhard ^a,e   Antlsperger, Astrid ^b   Welzel, Dieter ^b   Wambach, Gerhard ^c   Schardt, Wolfgang ^d   Weidinger, Gottfried ^a  

^a Novartis Pharma AG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Lungenklinik Merheim   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Novartis Pharma GmbH   (Germany)

Author keywords

ACE inhibitor; Calcium antagonist; Combination therapy; Controlled trial; Essential hypertension; Isradipine; Spirapril

Indexed keywords

CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISRADIPINE; SPIRAPRIL;

ADULT; AGED; ANKLE EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; ISRADIPINE; MALE; MIDDLE AGED;

EID: 0031474738     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007774505445     Document Type: Article

References (29)

1. Chalmers J. The place of combination therapy in the treatment of hypertension: A critical review. J Clin Hypertens 1987;3:178-193.
2. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: A critical review. J Clin Hypertens 1987;3:278-293.
3. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment. Am Heart J 1995;130: 359-366.
4. Pittrow DB, Krönig B, Kirch W, Weidinger G. Evaluation of reserpine and clopamide alone or in combination for first-line treatment of hypertension. Am J Hypertens 1996;6:712.
5. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: A critical review. J Clin Hypertens 1987;3:278-293.
6. Brunner HR, Ménard J, Waeber B, et al. Editorial Review: Treating the individual hypertensive patient: Considerations of dose, sequential monotherapy and drug combinations. J Hypertens 1990;8:3-11.
7. Kaplan NM. Combination therapy for hypertension. Am J Cardiol 1995;76:595-596.
8. Fitton A, Benfield P. Isradipine: A review of its pharmakodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990;40:31-74.
9. Noble S, Sorkin EM. Spirapril: A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs 1995;19:750-66.
10. Meredith PA, Grass P, Guitard C, Elliott HL. Pharmacokinetics of spirapril in renal impairment. Blood Pressure 1994:3(Suppl. 2):14-19.
11. MacConnachie AM, Maclean D. Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects? Drug Safety 1995;12:85-90.
12. Kirkendall WM, Feinleib M, Freis ED, Mark AL, et al. AHA Committee report: Recommendations for human blood pressure determination by sphygmomanometers. Hypertension 1981;3:510A-519A.
13. Bellet M, Sassano P, Guyenne T, Corvol P, Ménard J. Converting-enzyme buffers the counter-regulatory response to acute administration of nicardipine. Br J Clin Pharmacol 1987;24:465-472.
14. Morgan T, Anderson A, Hopper J. Enalapril and nifedipine in essential hypertension: Synergism of the hypotensive effects in combination. Clin Exp Hypertens 1988;A10:779-789.
15. Gennari C, Nami R, Pavese G, Gragnani S, Bianchini C, Buracchi P. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther 1989;3:319-325.
16. Müller FB, Bolli P, Linder L, Kiowski W, Erne P, Bühler FR. Calcium antagonists and the second drug for hypertensive therapy. Am J Med 1986;81(Suppl. 6A):25-29.
17. Di Somma S, Petitto M, Liguori V, Carotenuto A, Paulucci A, De Devitiis O. Antihypertensive effects of verapamil, captopril and their combination at rest and during dynamic exercise. Drug Res 1992;42:103-107.
18. Bainbridge AD, MacFadyen RJ, Stark S, Lees KR, Reid JL. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharmacol 1993;36: 323-330.
19. Bellet M, Whalen JJ, Bodin F, Serrurier, Tanner K, Ménard J. Use of cross-over trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. J Hypertens 1990;8(Suppl. 4):S43-S48.
20. Eggertsen R, Svensson A, Dahlöf B, Hansson L. Additive effect of isradipine in combination with captopril in hypertensive patients. Am J Med 1989;86(Suppl. 4A):124-126.
21. Fitscha P, Meisner W, Hinzberger G. Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension. J Cardiovasc Pharmacol 1991;18(Suppl 3):S12-S14.
22. Abarquez RF, Sy RG, Castillo RR. Efficacy of slow-release oral isradipine in moderate-to-severe hypertension with add-on spirapril. Am J Hypertens 1993;6:77S-79S.
23. Amir M, Christal N, Bar-On D, Loidl A. Does the combination of ACE-inhibitor and calcium antagonist control hypertension and improve quality of life? The LOMIR-MCT-IL study experience. Blood Pressure 1994;3(Suppl. 1):40-42.
24. Crout JR. Fixed combination prescription drugs: FDA policy. J Clin Pharmacol 1974;14:249-254.
25. Holzgreve H, Distler A, Michaelis J, Philipp T, Wellek S, on behalf of the Verapamil versus Diuretic (VERDI) Trial Research Group. Verapamil versus hydrochlorothiazide in the treatment of hypertension: Results of a long-term double blind comparative trial. Br Med J 1989;299:881-886.
26. Elliot HL, Meredith PA. Methodological considerations in calculation of the trough: peak ratio. J Hypertens 1994;12 (Suppl. 8):3-7.
27. Elliott HL, Merdith PA. Trough: peak ratio: Clinically useful or practically irrelevant? J Hypert 1995;13:279-283.
28. Food and Drug Administration. Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Rockville, MD: Division of Cardio-Renal Drug Products, U.S. Department of Health and Human Services, 1988.
29. Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990;3:151-155.